Grifols SA
GRFS
查看详细走势图
9.280USD
+0.090+0.98%
收盘 02/06, 16:00（美东）报价延迟15分钟
2.39B总市值
15.27市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.98%
5天
+0.32%
1月
+0.98%
6月
-11.45%
今年开始到现在
-0.75%
1年
+32.76%
查看详细走势图
TradingKey Grifols SA股票评分
单位: USD 更新时间: 2026-02-06操作建议
Grifols SA当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名71/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价12.20。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Grifols SA评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Grifols SA亮点
亮点风险
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
业绩高增长
公司营业收入稳步增长，连续3年增长22.33%
估值低估
公司最新PE估值15.27，处于3年历史低位
机构减仓
最新机构持股145.03M股，环比减少11.86%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值1.94K
分析师目标
根据
8
位分析师
买入
评级
12.200
目标均价
+32.75%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Grifols SA新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Grifols SA简介
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
公司代码GRFS
公司Grifols SA
CEOAbia (Jose Ignacio)
网址https://www.grifols.com/
相关品种
